GRI Bio, Inc. (GRI)Healthcare | Biotechnology | La Jolla, United States | NasdaqCM
2.55 USD
+0.06
(2.410%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.47 -0.08 (-0.080%) ⇩ (April 17, 2026, 5:55 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:48 p.m. EDT
GRI Bio, Inc. presents a highly volatile and uncertain investment opportunity. The stock has experienced significant price fluctuations, with a current price of $2.45, well below its 52-week low of $2.10. The recent price history shows a lack of clear momentum, with the stock fluctuating around the $2.30-$2.50 range. The negative beta of -1.24 indicates that the stock is inversely correlated with the market, which could be a double-edged sword during market downturns. The forward P/E ratio of -0.305 suggests that the stock is not currently profitable, and the negative earnings figures further support this. The company's fundamentals are weak, with negative return on assets and equity, indicating poor financial performance. The recent news headlines include both positive developments such as patent allowances and clinical trial results, but these have not translated into a significant increase in stock price. The reverse stock split and public offering may have impacted investor sentiment, leading to a decline in the stock price. Given the lack of dividends, weak fundamentals, and high volatility, GRI Bio is not a suitable investment for short-term traders or long-term investors. The stock is currently not a recommended investment due to its poor fundamentals and lack of consistent performance. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.431343 |
| AutoARIMA | 0.463865 |
| MSTL | 0.827799 |
| AutoETS | 0.880817 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 51% |
| H-stat | 3.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.215 |
| Excess Kurtosis | -1.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.182 |
| Market Cap | 3,684,824 |
| Forward P/E | -0.32 |
| Beta | -1.24 |
| Previous Name | Vallon Pharmaceuticals, Inc. |
| Website | https://www.gribio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9376223 |
| Address1 | 2,223 Avenida de la Playa |
| Address2 | Suite 208 |
| All Time High | 13,462,613.0 |
| All Time Low | 2.1 |
| Ask | 2.64 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 298,980 |
| Average Daily Volume3 Month | 384,713 |
| Average Volume | 384,713 |
| Average Volume10Days | 298,980 |
| Beta | -1.24 |
| Bid | 2.49 |
| Bid Size | 1 |
| Book Value | 12.072 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.55 |
| Current Ratio | 3.251 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.62 |
| Day Low | 2.52 |
| Debt To Equity | 1.182 |
| Display Name | GRI Bio |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -11,973,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.374 |
| Enterprise Value | -4,473,176 |
| Eps Current Year | -15.37 |
| Eps Forward | -8.025 |
| Eps Trailing Twelve Months | -121.8 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.4533 |
| Fifty Day Average Change | 0.09669995 |
| Fifty Day Average Change Percent | 0.039416276 |
| Fifty Two Week Change Percent | -93.76223 |
| Fifty Two Week High | 80.36 |
| Fifty Two Week High Change | -77.81 |
| Fifty Two Week High Change Percent | -0.96826774 |
| Fifty Two Week Low | 2.1 |
| Fifty Two Week Low Change | 0.45000005 |
| Fifty Two Week Low Change Percent | 0.21428575 |
| Fifty Two Week Range | 2.1 - 80.36 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,967,400,000 |
| Float Shares | 1,445,029 |
| Forward Eps | -8.025 |
| Forward P E | -0.317757 |
| Free Cashflow | -5,468,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 3 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00567 |
| Held Percent Institutions | 0.00147 |
| Implied Shares Outstanding | 1,445,029 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,769,385,600 |
| Last Split Factor | 1:28 |
| Long Business Summary | GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. |
| Long Name | GRI Bio, Inc. |
| Market | us_market |
| Market Cap | 3,684,824 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_136941170 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-18 |
| Net Income To Common | -11,956,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,728,174 |
| Number Of Analyst Opinions | 2 |
| Open | 2.52 |
| Operating Cashflow | -10,186,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 619 400 1170 |
| Post Market Change | -0.07999992 |
| Post Market Change Percent | -3.1372519 |
| Post Market Price | 2.47 |
| Post Market Time | 1,776,462,958 |
| Prev Name | Vallon Pharmaceuticals, Inc. |
| Previous Close | 2.49 |
| Price Eps Current Year | -0.1659076 |
| Price Hint | 4 |
| Price To Book | 0.2112326 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.114 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0599999 |
| Regular Market Change Percent | 2.40964 |
| Regular Market Day High | 2.62 |
| Regular Market Day Low | 2.52 |
| Regular Market Day Range | 2.52 - 2.62 |
| Regular Market Open | 2.52 |
| Regular Market Previous Close | 2.49 |
| Regular Market Price | 2.55 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 37,376 |
| Return On Assets | -1.03931 |
| Return On Equity | -2.38167 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,445,029 |
| Shares Percent Shares Out | 0.077800006 |
| Shares Short | 112,439 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 135,157 |
| Short Name | GRI Bio, Inc. |
| Short Percent Of Float | 0.077800006 |
| Short Ratio | 2.85 |
| Source Interval | 15 |
| State | CA |
| Symbol | GRI |
| Target High Price | 279.99988 |
| Target Low Price | 40.0 |
| Target Mean Price | 159.99994 |
| Target Median Price | 159.99994 |
| Total Cash | 8,229,000 |
| Total Cash Per Share | 5.695 |
| Total Debt | 71,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -121.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.678625 |
| Two Hundred Day Average Change | -27.128626 |
| Two Hundred Day Average Change Percent | -0.9140796 |
| Type Disp | Equity |
| Volume | 37,376 |
| Website | https://www.gribio.com |
| Zip | 92,037 |